RecruitingPhase 1NCT06146257

A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes

Studying Acute graft versus host disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
GluBio Therapeutics Inc.
Principal Investigator
Gang Lu, Ph.D.
GluBio Therapeutics Inc.
Intervention
GLB-001(drug)
Enrollment
48 enrolled
Eligibility
18 years · All sexes
Timeline
20242026

Study locations (8)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06146257 on ClinicalTrials.gov

Other trials for Acute graft versus host disease

Additional recruiting or active studies for the same condition.

See all trials for Acute graft versus host disease

← Back to all trials